Promega Corporation has authorised the RNA & Formulation Core at the University of British Columbia to manufacture and distribute mRNA constructs containing NanoLuc luciferase sequences. The agreement enables researchers working with mRNA and lipid nanoparticles to measure mRNA delivery and expression more effectively. NanoLuc is a small, highly stable bioluminescent reporter engineered by Promega that produces signals over 150 times brighter than conventional luciferase systems. When delivered and translated inside cells, it indicates whether mRNA reached its target and was successfully expressed—crucial for optimising therapeutic mRNA delivery systems. The UBC facility can now supply professionally produced, quality-controlled NanoLuc-encoding mRNA for research use, eliminating previous licensing and in-house production requirements. Applications include LNP delivery optimisation, mRNA vaccine development and gene therapy research.

Promega Corporation has announced a distribution agreement with NimaGen to expand access to the latter's IDseek massively parallel sequencing library prep kits for forensic laboratories. The partnership enables labs to access NimaGen's RC-PCR technology through Promega's established global network. NimaGen's IDseek portfolio includes over 20 products supporting applications such as autosomal STR profiling, Y-chromosomal analysis, microhaplotype analysis and mitochondrial DNA sequencing. The technology enables single closed-tube reactions designed for degraded and low-quantity forensic samples. The agreement allows forensic laboratories already using Promega's sample preparation and capillary electrophoresis tools to transition to massively parallel sequencing workflows whilst maintaining their existing supplier relationships. Promega has supported forensic laboratories for over 30 years across human identification workflows.